The In Vivo Fate of Polycatecholamine Coated Nanoparticles Is Determined by a Fibrinogen Enriched Protein Corona
Source abstract
Abstract
Polycatecholamine coatings have attracted significant attention in the past 10 years owing to their ability to functionalize a wide range of materials. Here we apply the use of such coatings to drug nanocrystals, made from a poorly soluble drug compound, to postfunctionalize the nanocrystal surface with the aim of providing steric stabilization and extending their circulation time after intravenous injection. We show that both polydopamine and polynorepinephrine can be used to successfully modify drug nanocrystals and subsequently incorporate end-functionalized PEG to the surface. Even though high grafting densities of PEG were achieved, we observed rapid clearance and increased liver uptake for polycatecholamine functionalized drug nanocrystals. Using both surface sensitive model systems and protein corona profiling, we determine that the rapid clearance was correlated with an increase in adsorption of proteins involved in coagulation to the polycatecholamine surface, with fibrinogen being the most abundant. Further analysis of the most abundant proteins revealed a significant increase in thiol-rich proteins on polycatecholamine coated surfaces. The observed interaction with coagulation proteins highlights one of the current challenges using polycatecholamines for drug delivery but might also provide insights to the growing use of these materials in hemostatic applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Blood properties and coagulation · Polymer Surface Interaction Studies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, 431 83 Gothenburg, Sweden
Department of Physics, Chalmers University of Technology, 41296 Gothenburg, Sweden
Bioscience Renal In Vivo Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden
Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden
Funding
AstraZeneca
References (58)
Show source-provided references
1. Lipinski C. · Am. Pharm. Rev. · 2002 · 5 · 82
2. 10.1016/S0928-0987(02)00251-810.1016/S0928-0987(02)00251-8 ↗
3. 10.1177/019262330731094610.1177/0192623307310946 ↗
4. 10.1002/smll.20160206610.1002/smll.201602066 ↗
5. 10.1021/nn204655410.1021/nn2046554 ↗
6. 10.1021/acsami.7b1986510.1021/acsami.7b19865 ↗
7. 10.1021/acsnano.8b0844510.1021/acsnano.8b08445 ↗
8. 10.1021/acsnano.8b0147010.1021/acsnano.8b01470 ↗
9. 10.1002/anie.20130164610.1002/anie.201301646 ↗
10. 10.1038/s41467-023-36303-810.1038/s41467-023-36303-8 ↗
11. 10.1126/science.114724110.1126/science.1147241 ↗
12. 10.1021/acsnano.9b0443610.1021/acsnano.9b04436 ↗
13. 10.1021/ac402274310.1021/ac4022743 ↗
14. 10.1038/embor.2010.3410.1038/embor.2010.34 ↗
15. 10.3390/ijms2117608010.3390/ijms21176080 ↗
16. 10.1021/acsami.5b0159010.1021/acsami.5b01590 ↗
17. 10.1021/acs.langmuir.8b0244410.1021/acs.langmuir.8b02444 ↗
18. 10.1016/j.jcis.2009.12.05210.1016/j.jcis.2009.12.052 ↗
19. 10.1016/0927-7757(95)03293-M10.1016/0927-7757(95)03293-M ↗
20. 10.1021/ja208433810.1021/ja2084338 ↗
21. 10.1016/j.ijpharm.2016.12.03510.1016/j.ijpharm.2016.12.035 ↗
22. 10.1016/j.ijpharm.2017.03.06210.1016/j.ijpharm.2017.03.062 ↗
23. 10.1021/la700811b10.1021/la700811b ↗
24. 10.1038/nmat471810.1038/nmat4718 ↗
25. 10.1038/nmat471810.1038/nmat4718 ↗
26. 10.1021/nn404117j10.1021/nn404117j ↗
27. 10.1038/nature1009810.1038/nature10098 ↗
28. 10.1074/mcp.M113.03159110.1074/mcp.M113.031591 ↗
29. 10.1093/nar/gky113110.1093/nar/gky1131 ↗
30. Gasteiger E. · 2005 · 57110.1385/1-59259-890-0:571 ↗
31. 10.1021/ac201778h10.1021/ac201778h ↗
32. 10.1238/Physica.Regular.059a0039110.1238/Physica.Regular.059a00391 ↗
33. 10.1021/ac010650110.1021/ac0106501 ↗
34. 10.1021/acs.jpcc.1c0450210.1021/acs.jpcc.1c04502 ↗
35. 10.1529/biophysj.103.03007210.1529/biophysj.103.030072 ↗
36. 10.1038/s41467-020-19295-710.1038/s41467-020-19295-7 ↗
37. 10.1038/358209a010.1038/358209a0 ↗
38. 10.1038/nm131410.1038/nm1314 ↗
39. 10.1007/s00401-021-02285-410.1007/s00401-021-02285-4 ↗
40. 10.1021/la981356f10.1021/la981356f ↗
41. 10.1016/S0006-3495(97)78698-310.1016/S0006-3495(97)78698-3 ↗
42. 10.1002/jbm.a.3646010.1002/jbm.a.36460 ↗
43. 10.1038/s41467-020-18237-710.1038/s41467-020-18237-7 ↗
44. 10.1021/ja037263o10.1021/ja037263o ↗
45. 10.1038/nnano.2010.25010.1038/nnano.2010.250 ↗
46. 10.1021/ja107583h10.1021/ja107583h ↗
47. 10.1126/sciadv.abc999210.1126/sciadv.abc9992 ↗
48. 10.1021/acsnano.7b0319010.1021/acsnano.7b03190 ↗
49. 10.1016/j.jconrel.2016.01.02010.1016/j.jconrel.2016.01.020 ↗
50. 10.1038/s41419-019-1806-810.1038/s41419-019-1806-8 ↗
51. 10.1016/j.addr.2022.11423810.1016/j.addr.2022.114238 ↗
52. 10.1016/j.ebiom.2020.10295810.1016/j.ebiom.2020.102958 ↗
53. 10.1021/acsomega.9b0130210.1021/acsomega.9b01302 ↗
54. 10.1038/pj.2014.4610.1038/pj.2014.46 ↗
55. 10.1002/adma.20090140710.1002/adma.200901407 ↗
56. 10.1038/s41467-021-21989-510.1038/s41467-021-21989-5 ↗
57. 10.1039/C9CS00285E10.1039/C9CS00285E ↗
58. Johannsmann, D. TU Clausthal─Institute for Physical Chemistry. https://www.pc.tu-clausthal.de/en/research/qcm-modelling/ (accessed on April 8, 2021).